Bayer Prepares for Critical Challenges Amid Xarelto Decline

Xarelto Decline:
Bayer faces significant challenges due to the decline of its blockbuster blood thinner Xarelto, with sales expected to drop by 12% from 2024 to 2025 and further to $459 million by 20262 5.

Patent Litigation:
Bayer is engaged in extensive patent litigation to protect Xarelto, including recent victories in Sweden and Belgium, but faces ongoing challenges in other European countries and the US3 5.

Earnings Impact:
Bayer reported a 37% decline in earnings per share in Q3 2024, largely due to Xarelto's decline and other headwinds, leading to a 12% drop in stock price1.

Strategic Plans:
Bayer is executing a multi-year strategy to boost performance, including a dynamic shared ownership model, supervisory board refresh, operating model overhaul, and cost efficiency measures1 4.

New Launches:
Bayer is focusing on new launches such as Nubeqa and Kerendia, which have shown strong uptake, and preparing for the launch of Acoramidis and Elinzanetant to drive future growth1 4.

2025 Outlook:
Bayer expects a muted outlook for 2025, with declining earnings, and plans to accelerate cost and efficiency measures to compensate1.